As of Mar 21
| +0.31 / +6.01%|
The 3 analysts offering 12-month price forecasts for Proteostasis Therapeutics Inc have a median target of 15.00, with a high estimate of 25.00 and a low estimate of 8.00. The median estimate represents a +174.22% increase from the last price of 5.47.
The current consensus among 4 polled investment analysts is to Buy stock in Proteostasis Therapeutics Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.